AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
20 May 2020 07:00 AM
RNS
Lynparza approved in the US for prostate cancer
18 May 2020 07:00 AM
RNS
Enhertu US Breakthrough status for lung cancer
18 May 2020 07:00 AM
RNS
Bevespi Aerosphere approved in China for COPD
11 May 2020 07:00 AM
RNS
Lynparza gets broader US ovarian cancer approval
11 May 2020 07:00 AM
RNS
Brazikumab rights recovered by AstraZeneca
11 May 2020 07:00 AM
RNS
Enhertu designated gastric cancer BTD
06 May 2020 07:00 AM
RNS
Farxiga approved by FDA for heart failure (HFrEF)
01 May 2020 03:00 PM
RNS
Total Voting Rights
29 Apr 2020 04:00 PM
RNS
Result of AGM
29 Apr 2020 07:00 AM
RNS
AZN: first-quarter 2020 results
24 Apr 2020 07:00 AM
RNS
Lynparza shows overall survival in prostate cancer
17 Apr 2020 11:00 AM
RNS
Changes to arrangements for AGM
14 Apr 2020 07:00 AM
RNS
Tagrisso adjuvant trial overwhelmingly positive
14 Apr 2020 07:00 AM
RNS
Koselugo (selumetinib) approved in the US for NF1
02 Apr 2020 07:00 AM
RNS
AstraZeneca divestment of Movantik completed
01 Apr 2020 03:00 PM
RNS
Total Voting Rights
31 Mar 2020 07:00 AM
RNS
Director/PDMR Shareholding
30 Mar 2020 07:01 AM
RNS
Imfinzi approved in US for small cell lung cancer
30 Mar 2020 07:00 AM
RNS
Farxiga CKD trial early stop for positive efficacy
26 Mar 2020 07:00 AM
RNS
Director/PDMR Shareholding
26 Mar 2020 07:00 AM
RNS
Lokelma approved in Japan for hyperkalaemia
24 Mar 2020 04:41 PM
RNS
Second Price Monitoring Extn
24 Mar 2020 04:36 PM
RNS
Price Monitoring Extension
24 Mar 2020 12:02 PM
RNS
Price Monitoring Extension
23 Mar 2020 04:40 PM
RNS
Second Price Monitoring Extn
23 Mar 2020 04:36 PM
RNS
Price Monitoring Extension
23 Mar 2020 12:08 PM
RNS
Second Price Monitoring Extn
23 Mar 2020 12:03 PM
RNS
Price Monitoring Extension
20 Mar 2020 10:20 AM
RNS
Second Price Monitoring Extn
20 Mar 2020 10:15 AM
RNS
Price Monitoring Extension
20 Mar 2020 07:00 AM
RNS
Director/PDMR Shareholding
19 Mar 2020 07:00 AM
RNS
Lynparza granted orphan drug designation in Japan
17 Mar 2020 07:00 AM
RNS
Imfinzi confirmed overall survival in CASPIAN
13 Mar 2020 04:35 PM
RNS
Price Monitoring Extension
12 Mar 2020 11:00 AM
RNS
Notice of AGM
12 Mar 2020 07:00 AM
RNS
Update on Phase III GY004 trial for cediranib
10 Mar 2020 07:00 AM
RNS
Director/PDMR Shareholding
06 Mar 2020 07:00 AM
RNS
Update on Phase III DANUBE trial in bladder cancer
04 Mar 2020 07:00 AM
RNS
Filing of Form 20-F with SEC
03 Mar 2020 11:00 AM
RNS
Annual Financial Report
02 Mar 2020 03:00 PM
RNS
Total Voting Rights
02 Mar 2020 07:00 AM
RNS
Divestment of hypertension medicines completed
27 Feb 2020 07:00 AM
RNS
Director/PDMR Shareholding
25 Feb 2020 07:00 AM
RNS
AstraZeneca divests global rights to Movantik
19 Feb 2020 07:00 AM
RNS
Director/PDMR Shareholding
19 Feb 2020 07:00 AM
RNS
Director/PDMR Shareholding
14 Feb 2020 07:00 AM
RNS
AZN: Full-year and Q4 2019 results
03 Feb 2020 03:00 PM
RNS
Total Voting Rights
27 Jan 2020 07:00 AM
RNS
Enhertu Phase II trial met primary endpoint
27 Jan 2020 07:00 AM
RNS
Brilinta met primary endpoint in stroke trial
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100